CCL3/MIP-1αIs a Potent Immunostimulator When Coexpressed with Interleukin-2 or Granulocyte-Macrophage Colony-Stimulating Factor in a Leukemia/Lymphoma Vaccine-Reference-Cited by-同舟云学术

CCL3/MIP-1αIs a Potent Immunostimulator When Coexpressed with Interleukin-2 or Granulocyte-Macrophage Colony-Stimulating Factor in a Leukemia/Lymphoma Vaccine

Published:2004-01 Issue:1 Volume:15 Page:21-34
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Zibert Andree¹,Balzer Stefan¹,Souquet Manfred¹,Quang Trong Hung¹,Paris-Scholz Cristina¹,Roskrow Marie²,Dilloo Dagmar¹

Affiliation:

1. Clinic for Pediatric Oncology, Hematology, and Immunology, University Hospital Dusseldorf, D-40225 Dusseldorf, Germany

2. GSF National Research Center for Environment and Health, D-85764 Munich, Germany

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/10430340460732436

Reference95 articles.

1. A new class of membrane-bound chemokine with a CX3C motif

2. Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens

3. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer.

4. The CC Chemokine CKβ-11/MIP-3β/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells Through NK Cells

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infection in Diabetes: Epidemiology, Immune Dysfunctions, and Therapeutics;Contemporary Diabetes;2024

2. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type;Exploration of Targeted Anti-tumor Therapy;2021-12-31

3. Therapeutic evaluation of immunomodulators in reducing surgical wound infection;The FASEB Journal;2021-12-14

4. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy;Cancer Immunology, Immunotherapy;2021-03-05

5. CCL3 Signaling in the Tumor Microenvironment;Advances in Experimental Medicine and Biology;2020